Hopewell Therapeutics
Woburn, MA · Biotechnology · 25 employees
Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell
Funding history
- Series seed — $2.5M — Sep 2025
- Funding Round — $7.8M — May 2024
- Series seed — $25.0M — Jun 2023
- Series seed — $3.0M — Jun 2023
- Funding Round — $7.1M — Feb 2022
Recent signals
- Sep 17, 2025: Raised $2.5M in Series seed
- May 17, 2024: Raised $7.8M
- Jun 07, 2023: Raised $25.0M in Series seed
- Jun 02, 2023: Raised $3.0M in Series seed
- Feb 02, 2022: Raised $7.1M
- Oct 08, 2021: Raised $8.0M
- Dec 21, 2020: Raised $7.8M
See plans & pricing → Track Hopewell Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.